title: Going back to class I: MHC and immunotherapies for childhood cancer.
abstract: After decades of unfulfilled promise, immunotherapies for cancer have reached a tipping point, with several FDA approved products now on the market and many more showing promise in both adult and pediatric clinical trials. Tumor cell expression of MHC class I has emerged as a potential determinant of the therapeutic success of many immunotherapy approaches. Here we review current knowledge regarding MHC class I expression in pediatric cancers including a discussion of prognostic significance, the opposing influence of MHC on T-cell versus NK-mediated therapies, and strategies to reverse or circumvent MHC down-regulation.
authors.affiliation: Division of Hematology/Oncology/Blood and Marrow Transplant, Nationwide Children's Hospital, Columbus, Ohio.
authors.forename: Kellie B
authors.initials: KB
authors.lastname: Haworth
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Leddon
authors.forename: Chun-Yu
authors.initials: CY
authors.lastname: Chen
authors.forename: Edwin M
authors.initials: EM
authors.lastname: Horwitz
authors.forename: Crystal L
authors.initials: CL
authors.lastname: Mackall
authors.forename: Timothy P
authors.initials: TP
authors.lastname: Cripe
mesh_terms: D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D015395:Histocompatibility Antigens Class I / Q000096:biosynthesis / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism / Q000637:transplantation; D008297:Male; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000637:transplantation
chemical_list: D015395:Histocompatibility Antigens Class I
keywords: MHC Class I; childhood cancers; immunotherapy